ERBB2 (HER2) protein expression in uterine sarcomas

European Journal of Gynaecological Oncology

Volumn 30, Issue 3, 2009, Pages 292-294

  Zafrakas, M ^a   Zepiridis, L ^a   Theodoridis, T D ^a   Venizelos, I D ^b   Papanicolaou, A ^a   Agorastos, T ^a   Bontis, J N ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Aristotle University and Hippokration General Hospital   (Greece)

Author keywords

ERBB2; HER2; Herceptin ; Lapatinib; Targeted therapy; Trastuzumab; Tykerb ; Uterine sarcoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PARAFFIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; UTERUS SARCOMA;

ADULT; AGED; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; MIDDLE AGED; RECEPTOR, ERBB-2; SARCOMA; UTERINE NEOPLASMS;

EID: 67649780123     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Zafrakas M., Theodoridis T.D., Zepiridis L., Venizelos I.D., Agorastos T., Bontis J.: "KIT protein expression in uterine sarcomas: an immunohistochemical study and review of the literature". Eur. J. Gynaecol. Oncol., 2008, 29, 264. (Pubitemid 351744490)
2. Forney J.P., Buschbaum H.J.: "Classifying, staging, and treating uterine sarcomas". Contemp. Ob. Gyn., 1981, 18, 47.
3. Nordal R.R., Thoreson S.O.: "Uterine sarcomas in Norway 1956-1992: incidence, survival and mortality". Eur. J. Cancer, 1997, 33, 907.
4. Kanjeekal S., Chambers A., Fung M.F., Verma S.: "Systemic therapy for advanced uterine sarcoma: a systematic review of the literature". Gynecol. Oncol., 2005, 97, 624. (Pubitemid 40614914)
5. Benoit L., Arnould L., Cheynel N., Goui S., Collin F., Fraisse J., Cuisenier J.: "The role of surgery and treatment trends in uterine sarcoma". Eur. J. Surg. Oncol., 2005, 31, 434. (Pubitemid 40521313)
6. Menczer J., Levy T., Piura B., Chetrit A., Altaras M., Meirovitz M. et al.: "A comparison between different postoperative treatment modalities of uterine carcinosarcoma". Gynecol. Oncol., 2005, 97, 166. (Pubitemid 40403689)
7. Yarden Y., Sliwkowski M.X.: "Untangling the ErbB signalling network". Nat. Rev. Mol. Cell. Biol., 2001, 2, 127.
8. Gschwind A., Fischer O.M., Ullrich A.: "The discovery of receptor tyrosine kinases: targets for cancer therapy". Nat. Rev. Cancer, 2004, 4, 361. (Pubitemid 38579482)
9. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L.: "Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene". Science, 1987, 235, 177. (Pubitemid 17231334)
10. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E. et al.: "Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer". Science, 1989, 244, 707. (Pubitemid 19147683)
11. Press M.F., Bernstein L., Thomas P.A., Meisner L.F., Zhou J.Y., Ma Y. et al.: "HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas". J. Clin. Oncol., 1997, 15, 2894. (Pubitemid 27330017)
12. Remmele W., Stegner H.E.: "[Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]". Pathologe, 1987, 8, 138.
13. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A. et al.: "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2". N. Engl. J. Med., 2001, 344, 783. (Pubitemid 32222155)
14. Vogel C.L., Cobleigh M.A., Tripathy D.: "Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer". J. Clin. Oncol., 2002, 20, 719. (Pubitemid 34111379)
15. Seidman A.D., Fornier M.N., Esteva F.J., Tan L., Kaptain S., Bach A. et al.: "Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification". J. Clin. Oncol., 2001, 19, 2587. (Pubitemid 32441364)
16. Romond E.H., Perez E.A., Bryant J.: "Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer". N. Engl. J. Med., 2005, 353, 1673. (Pubitemid 41464706)
17. Piccart-Gebhart M.J., Procter M., Leyland-Jones B.: "Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer". N. Engl. J. Med., 2005, 353, 1659. (Pubitemid 41464705)
18. Slamon D., Eiermann W., Robert N.: "Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with oxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and Trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study". Breast Cancer Res. Treat., 2005, 94, S5a.
19. Joensuu H., Kellokumpu-Lehtinen P.-L., Bono P.: "Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer". N. Engl. J. Med., 2006, 354, 809. (Pubitemid 43290919)
20. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T. et al.: "Lapatinib plus capecitabine for HER2-positive advanced breast cancer". N. Engl. J. Med., 2006, 355, 2733. (Pubitemid 46021510)
21. Burris H.A. 3rd, Hurwitz H.I., Dees E.C., Dowlati A., Blackwell K.L., O'Neil B. et al.: "Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas". J. Clin. Oncol., 2005, 23, 5305.
22. Cristofanilli M., Boussen H., Baselga J., Lluch A., Ben Ayed F., Friaha M. et al.: "A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC)". Breast. Cancer Res. and Treat., 2006, 100, S5.
23. Cimbaluk D., Rotmensch J., Scudiere J., Gown A., Bitterman P.: "Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets". Gynecol. Oncol., 2007, 105, 138. (Pubitemid 46441450)
24. Raspollini M.R., Susini T., Amunni G., Paglierani M., Castiglione F. et al: "Expression and amplification of HER-2/neu oncogene in uterine carcinosarcomas: a marker for potential molecularly targeted treatment?". Int. J. Gynecol. Cancer, 2006, 16, 416.
25. Livasy C.A., Reading F.C., Moore D.T., Boggess J.F., Lininger R.A.: "EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma". Gynecol. Oncol., 2006, 100, 101. (Pubitemid 41815057)
26. Sawada M., Tsuda H., Kimura M., Okamoto S., Kita T., Kasamatsu T. et al.: "Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma. 9". Cancer Sci., 2003, 94, 986. (Pubitemid 37508982)
27. Amant F., Vloeberghs V., Woestenborghs H., Debiec-Rychter M., Verbist L., Moerman P., Vergote I.: "ERBB-2 gene overexpression and amplification in uterine sarcomas". Gynecol. Oncol., 2004, 95, 583. (Pubitemid 39592525)
28. Nasu K., Kawano Y., Hirota Y., Matsui N., Hayata T., Miyakawa I.: "Immunohistochemical study of c-erb B-2 expression in malignant mixed müllerian tumors of the female genital tract". J. Obstet. Gynaecol. Res., 1996, 22, 347. (Pubitemid 26288331)
29. Swisher E.M., Gown A.M., Skelly M., Ek M., Tamimi H.K., Cain J.M. et al.: The expression of epidermal growth factor receptor, HER-2/Neu, p53, and Ki-67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma". Gynecol. Oncol., 1996, 60, 81.